Inclusion Criteria:

   - Documented lymphoid or myeloid neoplasm with 8p11 rearrangement known to lead to FGFR1
   activation, based on standard diagnostic cytogenetic evaluation performed locally,
   before signing informed consent for this study.

   - Eligible subjects must:

      - Have relapsed after stem cell transplantation or after other disease modifying
      therapy, OR

      - Not be current candidates for stem cell transplantation or other disease
      modifying therapies.

   - Note: All relapsed/refractory subjects must have evidence of either cytogenetic or
   hematological disease and have no evidence of residual toxicity (eg, graft-versus-host
   disease requiring treatment).

   - Life expectancy ≥ 12 weeks.

   - Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.

Exclusion Criteria:

   - Prior receipt of a selective FGFR inhibitor.

   - History and/or current evidence of ectopic mineralization/calcification, including but
   not limited to soft tissue, kidneys, intestine, myocardia, or lung, except calcified
   lymph nodes and asymptomatic arterial or cartilage/tendon calcifications.

   - Current evidence of corneal disorder/keratopathy, including but not limited to
   bullous/band keratopathy, corneal abrasion, inflammation/ulceration, and
   keratoconjunctivitis, as confirmed by ophthalmologic examination.

   - Use of any potent cytochrome P450 3A4 inhibitors or inducers within 14 days or 5
   half-lives (whichever is shorter) before the first dose of study drug.